Inhibition of protein arginine methyltransferase 3 activity selectively impairs liver X receptor‐driven transcription of hepatic lipogenic genes in vivo
Open Access
- 18 May 2018
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 175 (15) , 3175-3183
Abstract
Background and Purpose: Agonists for the liver X receptor (LXR) are considered promising therapeutic moieties in cholesterol‐driven diseases by promoting cellular cholesterol efflux pathways. However, current clinical application of these agents is hampered by concomitant LXR‐induced activation of a lipogenic transcriptional network, leading to hepatic steatosis. Recent studies have suggested that protein arginine methyltransferase 3 (PRMT3) may act as a selective co‐activator of LXR activity. Here, we verified the hypothesis that PRMT3 inhibition selectively disrupts the ability of LXR to stimulate lipogenesis while maintaining its capacity to modulate macrophage cholesterol homeostasis.Experimental Approach: A combination of the LXR agonist T0901317 and palm oil was administered to C57BL/6 mice to maximally stimulate LXR and PRMT3 activity. PRMT3 activity was inhibited using the allosteric inhibitor SGC707.Key Results: Treatment with SGC707 did not negatively influence the T0901317/palm oil‐induced up‐regulation of the cholesterol efflux ATP‐binding cassette transporter genes, ABCA1 and ABCG1, in peritoneal cells. In contrast, SGC707 treatment was associated with a significant decrease in the hepatic expression of the lipogenic gene fatty acid synthase (−64%). A similar trend was observed for stearoyl‐coenzyme A desaturase and acetyl CoA carboxylase expression (−43%; −56%). This obstruction of lipogenic gene transcription coincided with a significant 2.3‐fold decrease in liver triglyceride content as compared with the T0901317 and palm oil‐treated control group.Conclusion and Implications: We showed that inhibition of PRMT3 activity by SGC707 treatment selectively impairs LXR‐driven transcription of hepatic lipogenic genes, while the positive effect of LXR stimulation on macrophage cholesterol efflux pathways is maintained.Keywords
Funding Information
- Hartstichting (Grant 2007T056)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (VICI Grant 91813603)
- Hartstichting (2007T056)
- Hartstichting (2012T080)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (91813603)
This publication has 33 references indexed in Scilit:
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- The Isolation and Characterization of Murine MacrophagesCurrent Protocols in Immunology, 2008
- The Nuclear Receptor Cofactor, Receptor-Interacting Protein 140, Is Required for the Regulation of Hepatic Lipid and Glucose Metabolism by Liver X ReceptorMolecular Endocrinology, 2007
- Pharmacological Activation of Liver X Receptors Promotes Reverse Cholesterol Transport In VivoCirculation, 2006
- Controlling nuclear receptors: the circular logic of cofactor cyclesNature Reviews Molecular Cell Biology, 2005
- The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouseJournal of Lipid Research, 2003
- Stimulation of Cholesterol Excretion by the Liver X Receptor Agonist Requires ATP-binding Cassette Transporters G5 and G8Journal of Biological Chemistry, 2003
- Stimulation of Lipogenesis by Pharmacological Activation of the Liver X Receptor Leads to Production of Large, Triglyceride-rich Very Low Density Lipoprotein ParticlesJournal of Biological Chemistry, 2002
- Direct and Indirect Mechanisms for Regulation of Fatty Acid Synthase Gene Expression by Liver X ReceptorsJournal of Biological Chemistry, 2002
- Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβGenes & Development, 2000